Ivestatin Therapeutics

ivestatin therapeutics is a new spin-off from the research institute of the hospital de la santa creu i sant pau and gendiag, a barcelona-based biotechnology company. at ivestatin therapeutics we aim to become the world leader in innovative therapeutic solutions in the reduction of ischemic damage. shield4heart, our lead compound, is an innovative and safe first-line therapy to prevent and reduce ischemic damage following an acute coronary syndrome (acs) event, currently the world's leading cause of death. shield4heart reduces the infarct area by limiting ischaemic damage through a multitarget cell protection mechanism (mtcp) which is activated by atorvastatin. shield4heart is administered intravenously before reperfusion, the only method to obtain a rapid onset of action in acs. it can be introduced seamlessly into the acs clinical pathway with no disruption to current management protocols. to date, we have obtained promising in vivo data in several animal models (mouse, rat and pig)